ClearRead Xray - Compare
Riverain Technologies
|
Information source:
Vendor
Last updated: June 20, 2022 |
General Information
| General | |
|---|---|
| Product name | ClearRead Xray - Compare |
| Company | Riverain Technologies |
| Subspeciality | Chest |
| Modality | X-ray |
| Disease targeted | Lung cancer |
| Key-features | Multiple time-point analysis |
| Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand) |
Technical Specifications
| Data characteristics | |
|---|---|
| Population | Adult, not pediatric |
| Input | Current and prior PA/AP chest view, showing both lungs |
| Input format | DICOM |
| Output | Differences between current and prior images as grayscale values ranging from dark to light. |
| Output format | DICOM Secondary Capture |
| Technology | |
| Integration | Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform |
| Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker) |
| Trigger for analysis | Automatically, right after the image acquisition |
| Processing time | 1 - 10 minutes |
Regulatory
| Certification | |
|---|---|
| CE |
Certified,
Class IIa
, MDR
|
| FDA | 510(k) cleared , Class II |
| Intended Use Statements | |
| Intended use (according to CE) | Compare is intended to generate a secondary residual image based on a current and prior chest x-ray image of the same patient, resulting in improved visibility of lung nodules. The Compare image provides adjunctive information and is not a substitute for the original PA/AP image. This device is intended to be used by trained professionals, such as physicians, radiologists, and technicians on patients with risk of having lung nodules and is not intended to be used on pediatric patients. |
Market
| Market presence | |
|---|---|
| On market since | 12-2011 |
| Distribution channels | Sectra Amplifier Store, Aidoc aiOS, Volpara Health, GE Healthcare |
| Countries present (clinical, non-research use) | 13 |
| Paying clinical customers (institutes) | 200+ |
| Research/test users (institutes) | 6 |
| Pricing | |
| Pricing model | Subscription, One-time license fee |
| Based on | Number of analyses |
Evidence
| Evidence | |
|---|---|
| Peer reviewed papers on performance | |
| Non-peer reviewed papers on performance | |
| Other relevant papers | |